Spots Global Cancer Trial Database for tyrosine kinase inhibitors
Every month we try and update this database with for tyrosine kinase inhibitors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting | NCT00877045 | Gastrointestina... | 18 Years - | SCRI Development Innovations, LLC | ||
| Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor | NCT03907670 | Chronic Phase C... | 20 Years - 80 Years | Assiut University | ||
| Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial | NCT05382741 | Colorectal Canc... No Evidence of ... | Durvalumab Inje... Regorafenib 30 ... | 18 Years - | Ospedale Policlinico San Martino | |
| Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia | NCT04006847 | Chronic Myeloid... | Eicosapentaenoi... Tyrosine kinase... | 18 Years - | Milton S. Hershey Medical Center | |
| Pegasys in Patients With Chronic Myeloid Leukemia (CML) | NCT01392170 | Leukemia | PEG-IFNá-2a | 16 Years - | M.D. Anderson Cancer Center | |
| Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia | NCT01768689 | Leukemia, Myelo... Medication Adhe... | Adherence-encou... Adherence-encou... Adherence-encou... | 18 Years - | Rabin Medical Center | |
| Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors | NCT01700699 | Differentiated ... | - | University of Salerno | ||
| Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) | NCT01999985 | Lung Cancer Non-small Cell ... | Dasatinib - 1A Afatinib - 1A Dasatinib - 1B Afatinib - 1B | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs | NCT01098500 | Cancer | Tyrosine kinase... | 18 Years - | GlaxoSmithKline | |
| Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women | NCT01227928 | Neoplasms, Ovar... | Pazopanib Placebo compara... | 18 Years - | GlaxoSmithKline | |
| Pegasys in Patients With Chronic Myeloid Leukemia (CML) | NCT01392170 | Leukemia | PEG-IFNá-2a | 16 Years - | M.D. Anderson Cancer Center | |
| Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase | NCT04070443 | Philadelphia Ch... BCR-ABL Positiv... | Ponatinib Imatinib | 18 Years - 65 Years | Centre Leon Berard | |
| Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy | NCT02787447 | Lung Adenocarci... | TKI Thoracic Hypofr... Thymosin Alpha ... | 18 Years - 75 Years | First People's Hospital of Hangzhou | |
| CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) | NCT04151342 | Cancer Malignancies Mu... Malignant Solid... Cancer, Therapy... Molecular Seque... Genetic Alterat... Gene Fusion Receptor Tyrosi... RTK Family Gene... Ras (Kras or Nr... | Cancer treatmen... Patient-reporte... | 18 Years - | University Health Network, Toronto | |
| Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | NCT00990249 | Leukemia Lymphoma Allogeneic Haem... Acute Lymphobla... | Busulfan Clofarabine Thymoglobulin Stem Cell Trans... | - 65 Years | M.D. Anderson Cancer Center | |
| A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) | NCT04578847 | Chronic Myeloid... Chronic Myeloid... BCR-ABL Positiv... | Imatinib Nilotinib Dasatinib Bosutinib | 18 Years - | National Research Center for Hematology, Russia | |
| A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma | NCT05590572 | Osteosarcoma | Sulfatinib Etoposide Isophosphamide | 2 Years - 25 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase | NCT05143840 | Chronic Myeloid... Adult CML Leukemia, Myelo... Leukemia,Myeloi... | Asciminib Ascimininb + Ni... Asciminib + Ima... Asciminib + Das... | 18 Years - | Augusta University | |
| A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors | NCT04605211 | Myeloproliferat... Chronic Phase C... Chronic Myeloid... | Online Mindfuln... Internet-Based ... | 18 Years - | University of California, San Francisco | |
| Doxycycline vs Isotretinoin for Acneiform Eruptions of TKI | NCT04864717 | Acneiform Erupt... Cancer, Treatme... | Doxycycline 100... Isotretinoin 40... | 18 Years - | Lady Davis Institute | |
| A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma | NCT05590572 | Osteosarcoma | Sulfatinib Etoposide Isophosphamide | 2 Years - 25 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| AZD9291 in Combination With Ascending Doses of Novel Therapeutics | NCT02143466 | Advanced Non Sm... | Part A - AZD929... Part A - AZD929... Part A - AZD929... Part A - AZD929... Part A - AZD929... Part B - AZD929... Part B - AZD929... Part B - AZD929... Part C - AZD609... Part C - AZD929... Part D - AZD929... | 18 Years - 130 Years | AstraZeneca | |
| Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women | NCT01227928 | Neoplasms, Ovar... | Pazopanib Placebo compara... | 18 Years - | GlaxoSmithKline | |
| Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV) | NCT03680183 | Non Small Cell ... Hepatitis B | Entecavir 1Mg O... | 18 Years - 70 Years | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | |
| An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib | NCT01932229 | NSCLC | Afatinib treatm... | - | Sheba Medical Center | |
| Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System | NCT05753384 | Tyrosine Kinase... Chronic Myeloid... | treatment of TK... | 18 Years - | Poitiers University Hospital | |
| Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC. | NCT06167460 | Non Small Cell ... Stage IIIB Non-... Stage IIIC Non-... Stage IV Non-sm... Tyrosine Kinase... | 18 Years - 80 Years | Gene Solutions | ||
| Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer | NCT02718651 | Carcinoma, Non-... | 18 Years - | University of Aarhus | ||
| Identification of Novel Biomarkers of Response to Systemic Treatments in Renal Cell Cancer | NCT04060537 | Carcinoma, Rena... | Laboratory anal... Application of ... | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | NCT00990249 | Leukemia Lymphoma Allogeneic Haem... Acute Lymphobla... | Busulfan Clofarabine Thymoglobulin Stem Cell Trans... | - 65 Years | M.D. Anderson Cancer Center | |
| A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors | NCT03424980 | Non-small Cell ... | Tyrosine kinase... | - | Tang-Du Hospital | |
| Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation | NCT04838041 | Chronic Phase C... | Asciminib 40 MG Asciminib 40 MG... Asciminib 80 MG... Imatinib Nilotinib Dasatinib | 18 Years - | Medical College of Wisconsin | |
| A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors | NCT03424980 | Non-small Cell ... | Tyrosine kinase... | - | Tang-Du Hospital | |
| Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00866697 | Ovarian Cancer | Pazopanib Placebo | 18 Years - | Novartis | |
| A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | NCT04042116 | Advanced Solid ... Gynecologic Can... | Lucitanib Lucitanib Lucitanib Nivolumab | 18 Years - | Clovis Oncology, Inc. | |
| Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation | NCT06427811 | Philadelphia Ch... | Asciminib | 18 Years - | Novartis | |
| Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST | NCT05751733 | Gastrointestina... | Apatinib Mesyla... Sunitinib, Imat... | 18 Years - | Xiangya Hospital of Central South University | |
| Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase | NCT04070443 | Philadelphia Ch... BCR-ABL Positiv... | Ponatinib Imatinib | 18 Years - 65 Years | Centre Leon Berard | |
| Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST | NCT05751733 | Gastrointestina... | Apatinib Mesyla... Sunitinib, Imat... | 18 Years - | Xiangya Hospital of Central South University | |
| A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | NCT04042116 | Advanced Solid ... Gynecologic Can... | Lucitanib Lucitanib Lucitanib Nivolumab | 18 Years - | Clovis Oncology, Inc. | |
| Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase | NCT05143840 | Chronic Myeloid... Adult CML Leukemia, Myelo... Leukemia,Myeloi... | Asciminib Ascimininb + Ni... Asciminib + Ima... Asciminib + Das... | 18 Years - | Augusta University | |
| Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation | NCT04838041 | Chronic Phase C... | Asciminib 40 MG Asciminib 40 MG... Asciminib 80 MG... Imatinib Nilotinib Dasatinib | 18 Years - | Medical College of Wisconsin | |
| Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) | NCT01999985 | Lung Cancer Non-small Cell ... | Dasatinib - 1A Afatinib - 1A Dasatinib - 1B Afatinib - 1B | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors | NCT01700699 | Differentiated ... | - | University of Salerno | ||
| Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. | NCT05311943 | Olverembatinib Chronic Myeloid... Tyrosine Kinase... | olverembatinib | 18 Years - 75 Years | Shenzhen Second People's Hospital | |
| TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN) | NCT04760431 | HER2-positive B... Brain Metastase... | Trastuzumab Taxanes Pertuzumab Tyrosine kinase... | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib | NCT01932229 | NSCLC | Afatinib treatm... | - | Sheba Medical Center | |
| Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. | NCT05311943 | Olverembatinib Chronic Myeloid... Tyrosine Kinase... | olverembatinib | 18 Years - 75 Years | Shenzhen Second People's Hospital | |
| Pegasys in Patients With Chronic Myeloid Leukemia (CML) | NCT01392170 | Leukemia | PEG-IFNá-2a | 16 Years - | M.D. Anderson Cancer Center | |
| Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia | NCT01768689 | Leukemia, Myelo... Medication Adhe... | Adherence-encou... Adherence-encou... Adherence-encou... | 18 Years - | Rabin Medical Center | |
| Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC | NCT06041477 | Hepatocellular ... Chemotherapy Ef... Chemotherapeuti... | Oxaliplatin,cal... Concurrent Lenv... Concurrent PD-1... Sequential Lenv... Sequential PD-1... | 18 Years - 75 Years | Sun Yat-sen University | |
| Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy | NCT00343759 | Breast Cancer | Lapatinib | 18 Years - | University of Pennsylvania | |
| Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure | NCT04193553 | Gastro Intestin... | Lenvatinib Placebo Best supportive... | 18 Years - | Centre Leon Berard | |
| A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL | NCT05024357 | Precursor Cell ... Philadelphia-Po... ALL, Adult | Dasatinib | 18 Years - 65 Years | First Affiliated Hospital Xi'an Jiaotong University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
